InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results
InterCure reported strong financial results for Q4 2021 with record revenue of $33 million, a 29% sequential growth, and annual revenue of $89 million, marking a 230% increase year-over-year. Adjusted EBITDA reached $9 million, reflecting a 140% rise from the previous year. The company maintains a solid balance sheet with $89 million in cash. Positive developments include the expansion into Europe, signing a definitive agreement to acquire Better, and a partnership with Charlotte's Web targeting the new CBD market. InterCure continues to capture approximately 30% of Israel’s medical cannabis market.
- Record Q4 2021 revenue of $33 million, up 29% sequentially.
- Full-year 2021 revenue of $89 million, a 230% increase YoY.
- Adjusted EBITDA for Q4 2021 at $9 million, increasing 140% YoY.
- Solid balance sheet with $89 million cash supports future growth.
- Successful expansion into Europe with Cookies™ retail locations.
- Acquisition agreement for Better, enhancing market position.
- Partnership with Charlotte's Web targeting new CBD market.
- Net income loss of $1 million for Q4 2021.
- Ongoing operational challenges exceeding net losses.
Another record year with continued industry leading growth and profitability supported by focused strategy and execution
Revenue growth expected to continue in the first quarter and throughout 2022
Strong balance sheet with
NEW YORK and TORONTO and HERZLIYA, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2021. References herein to “preliminary results” refer to the preliminary results published by the Company on February 8, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted.
Fourth Quarter 2021 Key Financial & Operating Highlights
- Record revenue of
$33 million (NIS 80 million), which is higher than the preliminary results, and three times greater than the fourth quarter of 2020 and representing sequential growth of29% . - Record adjusted EBITDA of
$9 million (NIS 21 million), representing a140% increase year-over-year, sequential growth of almost50% and adjusted EBITDA margin of26% . - Net income loss of
$1 million (NIS 3 million) for the fourth quarter of 2021. - Exceeded preliminary results with its eighth consecutive quarter of high double-digit growth representing an estimated annualized run rate of over
$130 million (NIS 320 million). - Sixth consecutive quarter of positive cash flow from operations.
- Announced European expansion with international cannabis brand Cookies™ - opening first retail locations in Austria and the United Kingdom.
- Company surpassed one-ton medical cannabis products dispensed per month in the fourth quarter, representing approximately
30% market share of Israel’s medical cannabis.
Full Year 2021 Key Financial & Operating Highlights
- Record fiscal year 2021 revenue and Adjusted EBITDA of
$89 million (NIS 220 million) and$23 million (NIS 55 million), representing an increase of230% and250% year-over-year, respectively. - Adjusted EBITDA margin of
25% for the fiscal year 2021 up1% from 2020. - Cash at year end of
$89 million (NIS 217 million). - Net income of
$3 million (NIS 7 million) for 2021. - Increased market share due to solid demand for Canndoc's branded products and expansion of the Company’s medical cannabis dispensing operations.
- Added 19 locations to its leading medical cannabis dedicated pharmacy chain, out of which 13 are actively dispensing medical cannabis.
- Announced the first major consolidation in the pharmaceutical medical cannabis space with the signing of an LOI to acquire multi-national licensed producer "Better".
- Solid international demand for InterCure’s GMP branded products expected to boost global expansion as Israeli government eases regulation on exportation.
- Legislation of adult use cannabis and CBD products in Israel progresses as a new government sworn into office in June 2021.
- InterCure commenced trading on Nasdaq.
- During the third quarter, InterCure received 5.2 million shares back from the sponsor of our SPAC transaction.
- CEO Alexander Rabinovitch purchased on the open market a total of 423,501 shares of the Company’s common stock for a total investment in the Company of
$3,790,238 or NIS 9,608,631.
Post-fourth quarter 2021 Highlights
- Announced it has signed a definitive agreement to acquire
100% of Better's shares. - Announced international strategic partnership with Clever Leaves.
- Company expected to capitalize on new CBD market following the Israeli Minister of Health's announcement that CBD will be removed from the Dangerous Drugs Act through strategic partnership with Charlotte's Web.
- Signed definitive agreement with Altman Health, the leading Israeli wellness brand with distribution into 1,700 points of sale, focusing on the new Israeli CBD product market.
- Added 3 new medical cannabis dedicated pharmacies to the Company's chain, totaling 23 retail locations across Israel, out of which 15 are actively dispensing medical cannabis.
“Our fourth quarter results came in stronger than we initially expected as we successfully continue to expand InterCure's branded product portfolio, scale up our unique global supply chain and expand our pharmaceutical grade medical cannabis dispensing operation,” said InterCure CEO Alexander Rabinovitch, adding “Our results throughout 2021 reflect the outstanding work we've accomplished and our focus on executing our profitable growth strategy. As regulations are evolving favorably, there is huge potential in all of our operating territories, and we are well positioned for the growth ahead. We will continue focusing on executing our profitable growth strategy, creating value for our stakeholders."
Key Q4 and Full Year 2021 Financial Highlights – Cannabis Sector
(In thousands $)
| Full Year | 2020 | 2021 (Preliminary) | 2021 |
| Revenues | 26,628 | 87,000 | 88,779 |
| Gross Profit(1) | 12,441 | 37,799 | |
| Adjusted EBITDA(2) | 6,508 | 22,566 |
| Fourth Quarter | Q4-20 | Q4-21 (Preliminary) | 2021 |
| Revenues | 11,093 | 31,000 | 32,632 |
| Gross Profit(1) | 5,446 | 14,990 | |
| Adjusted EBITDA(2) | 3,549 | 8,635 |
| Q2-20 | Q3-20 | Q4-20 | Q1-21 | Q2-21 | Q3-21 | Q4-21 | ||||||||
| Revenues | 4,580 | 9,211 | 11,093 | 13,532 | 18,518 | 25,260 | 32,632 | |||||||
| Gross Profit(1) | 1,971 | 4,403 | 5,446 | 6,316 | 7,889 | 10,106 | 14,990 | |||||||
| GP Margin | 46% | |||||||||||||
| Adjusted EBITDA(2) | 644 | 2,852 | 3,549 | 4,121 | 4,791 | 5,749 | 8,635 | |||||||
| Adjusted EBITDA(2) Margin | 26% |
(1) Gross profit before effect of fair value.
(2) EBITDA adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This is a non-IFRS financial measure and does not have a standardized meaning prescribed by IFRS, please see “Non-IFRS Measures” below.
Rescheduled Webcast and Conference Call
Management will conduct a webcast on Wednesday, April 6, 2022 at 5:30 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy.
To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207.
Participants can access the live webcast through the following link:
https://bit.ly/37N92wN
Consolidated Financial Statements and Management's Discussion and Analysis
The publication of InterCure's audited financial statements and accompanying notes for the year ended December 31, 2021 and related management's discussion and analysis of financial condition and results of operations ("MD&A") are available under the Company's profile on SEDAR.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Non-IFRS Measures
This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. A reconciliation of Adjusted EBITDA to an IFRS measure (revenue) is provided below:
| Adjusted EBITDA Reconciliation (consolidated base) | FOURTH QUARTER | FULL YEAR | |||||
| Q4-20 | Q4-21 | 2020 | 2021 | ||||
| Comprehensive income (loss) | 4,188 | (1,244) | (14,756) | 2,987 | |||
| Interest / Financing cost | (94) | 2,659 | (38) | 3,870 | |||
| Tax expenses (income) | (1,042) | 2,291 | (929) | 4,684 | |||
| Depreciation and amortization | 438 | 1,314 | 1,332 | 3,027 | |||
| EBITDA | 3,491 | 5,020 | (14,391) | 14,568 | |||
| Share-based payment expenses | 686 | 479 | 4,098 | 2,641 | |||
| Other expenses (income), net | 381 | 643 | 1,868 | 1,217 | |||
| Impairment losses and (gains) on financial assets through profit and loss | (1,085) | 901 | 15,229 | 765 | |||
| Fair value adjustment to inventory | (129) | 920 | (650) | 1,989 | |||
| Adjusted EBITDA | 3,344 | 7,963 | 6,154 | 21,179 | |||
*All amounts shown in CAD
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to InterCure’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes”, “hopes”, “may”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”, “estimates”, “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s future revenue growth and profitability, the success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic and the war in Ukraine. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in Subversive Acquisition LP’s final long form prospectus dated March 15, 2021, which is available on SEDAR at www.sedar.com, and under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on July 14, 2021, as amended August 3, 2021 and August 18, 2021. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
Amos@intercure.co
FAQ
What was InterCure's revenue in Q4 2021?
How much cash does InterCure have?
What is the expected revenue growth for InterCure in 2022?
What significant partnerships has InterCure formed recently?
How does InterCure's market share in medical cannabis look?
